ArticleIn vivo (Athens, Greece)
Ramelteon Mitigates Cisplatin-induced Testicular Dysfunction in Rats.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimCisplatin is a widely used anti-cancer agent, but it can cause testicular dysfunction, leading to infertility and hypogonadism. Currently, pharmacological agents for preventing testicular dysfunction during chemotherapy are limited. Ramelteon, an insomnia medication that selectively targets melatonin receptor type 1 and type 2, exerts cytoprotective effects across organs via anti-inflammatory and anti-apoptotic mechanisms. Ramelteon has an established safety profile in humans; however, its efficacy against chemotherapy-induced testicular toxicity remains unclear. We therefore examined the protective efficacy of ramelteon against cisplatin-induced testicular dysfunction in a rat model. MATERIALS AND
methodsMale 8-week-old Jcl:Wistar rats were randomized to control (saline+vehicle), ramelteon (10 mg/kg/day orally on days 1-7), cisplatin (7 mg/kg intraperitoneally once on day 1), or cisplatin+ramelteon (n=8 per group). On day 8, blood, testes, and epididymides were collected. Endpoints included sperm parameters, testicular histopathology, Ki-67 immunostaining, serum testosterone, and testicular quantitative polymerase chain reaction (qPCR) for steroid synthesis-related (
resultsCisplatin administration induced histological damage to the seminiferous tubules, reduced sperm counts and motility, decreased testosterone levels, increased testicular interstitial Ki-67 positivity, suppressed steroid synthesis-related gene expression, and increased apoptosis-related and inflammation-related gene expression. Co-administration of ramelteon significantly attenuated these changes, resulting in reduced pathological tissue damage in the testes, attenuation of deterioration in sperm parameters and testosterone levels, and improvement in steroid synthesis-related and inflammation-related gene expression.
conclusionRamelteon mitigated acute cisplatin-induced testicular damage in rats by attenuating deterioration in sperm parameters and steroidogenesis-related changes. These findings suggest that ramelteon may be a candidate for further investigation as a strategy to mitigate acute chemotherapy-induced testicular injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.